Intuitive Surgical delivered a robust quarterly performance, reporting revenue of $2.87 billion, up 18.8% year-over-year, and non-GAAP EPS of $2.53, exceeding consensus estimates by $0.26. The company achieved a net margin of 28.38% and a return on equity of 15.06%. However, management’s forward guidance fell short of analyst expectations, citing a moderation in system placements and consumable sales growth for the upcoming quarter, which tempers near-term revenue visibility despite strong underlying demand trends.

Alpha Cubed Investments LLC increased its stake by 13.0%, adding 10,677 shares to reach 92,600 shares, representing 1.4% of its portfolio and valued at $41.4 million at quarter-end. Other hedge funds also boosted positions: Valley Wealth Managers +52.7% to 4,084 shares; Tandem Investment Advisors +4.5% to 9,219 shares; Strategic Advisors +63.3% to 10,397 shares; AE Wealth Management +18.9% to 11,556 shares; LRI Investments +24.0% to 1,997 shares. Insider sell-down included 4,500 shares by the SVP for proceeds of $2.46 million and 13,731 shares by the EVP for $7.96 million, contributing to a total of 75,557 shares sold by insiders over 90 days, valued at approximately $42 million.

The FDA granted expanded clearance for the da Vinci 5 system to perform select advanced cardiac procedures, unlocking a significant new addressable market for both system installations and recurring consumable revenues. Following this clearance, TD Cowen upgraded coverage to Strong Buy, Barclays reaffirmed its Buy rating, and HSBC raised its price-appreciation forecast, collectively reinforcing positive analyst sentiment. At the same time, valuation remains debated: Evercore ISI trimmed its target while other firms lifted theirs, resulting in a consensus Moderate Buy and an average price target of $620.41.

Intuitive Surgical’s leadership in robotic-assisted surgery continues to attract conviction from long-term growth investors such as Polen Capital, which cites the da Vinci platform’s decades-long clinical adoption curve. With a diversified consumables business and service recurring revenue model, the company is positioned to capitalize on increasing procedure volumes and geographic expansion. Management’s ongoing investment in next-generation platforms and software enhancements underpins a multi-year revenue tail, and analysts project full-year EPS of approximately 6.43, reflecting double-digit growth potential beyond near-term guidance fluctuations.